Gastrointestinal and liver disease-focused Metacrine has filed to go public having raised $125m from investors including Eli Lilly.

Volvo Cars, Corning and Cornes-backed lidar technology developer Luminar is merging with a special purpose acquisition vehicle to form a company with an expected $3.4bn valuation.

The SK Telecom, iA Financial, Foxconn and Fujifilm-backed X-ray technology developer priced the offering at the top of its range.

The protein degradation drug developer's valuation has rocketed following an offering that achieved exits for Vertex Pharmaceuticals, Pfizer, Sanofi, Amgen and Merck & Co.

Eli Lilly and WuXi Biologics-backed biologics developer Inhibrx floated at the midpoint of its range having previously raised $135m in debt and equity financing.

GlaxoSmithKline Eli Lilly and Genmab-backed messenger RNA drug developer CureVac priced the offering at the top of its range.

Tencent is buying $160m of shares in the real estate platform's initial public offering, which also provides an exit for SoftBank Vision Fund.

SAIC Capital has scored an exit less than two years after it invested in the now publicly-listed intelligent manufacturing technology provider.

The Humana-backed primary care provider has closed its initial public offering after its share price more than doubled post-IPO.

The cancer treatment developer floated in the middle of its range following $175m in venture funding from investors including Novo.